Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone TherapySafety of LBH589 Alone and in Combination With IV Docetaxel and PrednisoneEfficacy and Safety of Everolimus in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Targeted Therapy and ChemotherapyStudy of Pralatrexate With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Peripheral T-cell LymphomaA Study to Investigate the Effects of Ketoconazole on LBH589 in Patients With Advanced Solid TumorsA Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant MelanomaCytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid LeukemiaStudy to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/LeukemiaMonoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney CancerStudy of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL)A Study of ASA404 or Placebo in Combination With Docetaxel in Second-line Treatment for (Stage IIIb/IV) Non-small Cell Lung CancerMelphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple MyelomaA Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Erdafitinib Plus JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Metastatic or Surgically Unresectable Urothelial Cancer With Selected FGFR GeneChemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery
P6153
Q58844415-45618E36-0358-490C-B747-4B9E281E99CFQ58848980-FBD4F66F-1F8F-451D-8972-67A7A76E1226Q61917771-711CA1B5-6A91-4A4E-8E05-FB08A85246BBQ61922110-3DF5D99F-8366-486B-A64B-C85521565DB8Q61934419-B5DB8BD3-F6F8-4DC0-AE62-B8A484B7C537Q61980167-EC439A48-5B89-4D11-BE21-E549ED5DCC57Q61981180-B9F4F93D-D9FA-444C-96C8-4D1AE784E8D8Q62105041-E377B1CD-A498-460B-BCB2-6114453F8666Q62105795-D5B1DFAF-25D0-4A34-9EED-3A3C20B5C6BDQ62110444-E05F85C3-E62B-4DF1-9B3F-DD310E41DC8FQ62110547-8A623046-3C11-4F57-A9E1-178DAA00684EQ63063081-ADAE0C7E-10D9-4623-94A1-E5BCF5CC498CQ63571770-693D7560-3D7C-4110-BCEB-41D508E9BBA9Q63571964-D41D02C5-8101-4652-8C96-18BBA467A455Q64171079-9697ECCE-65E2-4737-BE42-98241ABC8D5B
P6153
name
Nevada Cancer Institute
@en
type
label
Nevada Cancer Institute
@en
prefLabel
Nevada Cancer Institute
@en
P214
P244
P6366
P131
P214
P244
no2008041976
P6366
1311717221
P7859
lccn-no2008041976